Connect with us

Government

Week Ahead: The First Look at US and EMU Q3 GDP and more Tapering by the Bank of Canada

The macro highlights for the week ahead fall into three categories.  First are the preliminary estimates for Q3 GDP by the US and the EMU.  Second, are the inflation reports by the same two.  The US sees the September PCE deflator, which the Fed targets,.

Published

on

The macro highlights for the week ahead fall into three categories.  First are the preliminary estimates for Q3 GDP by the US and the EMU.  Second, are the inflation reports by the same two.  The US sees the September PCE deflator, which the Fed targets, while the eurozone releases the first estimate for October CPI.  Third are the meetings of three G7 central banks, the BOJ, the ECB, and the Bank of Canada. 

The broad backdrop includes softening PMI readings, the continued rise in oil prices, and a sharp backing up of interest rates.   On the eve of last month's FOMC meeting conclusion, the August 2022 Fed funds future contract implied an average effective rate of 11 bp.   It is now yielding almost 32 bp, nearly completely discounting a 25 bp rate hike at the late July 2022 FOMC meeting as there is no meeting in August next year.  

The nearly seven basis point decline in the 10-year US Treasury yield ahead of the weekend brought the yield increase to about 33 bp since the September FOMC meeting.  However, this reflects a rise in inflation expectations primarily.  The 10-year breakeven (the difference between the conventional 10-year bond yield and the 10-year Treasury inflationary-protected security) has also risen by about 33 bp over the same time.  

Since the beginning of September, the implied yield of the December 2021 short-sterling interest rates futures contract has risen by a similar 34 bp, as the market anticipates the beginning of a tightening cycle this year, and that is after the yield has eased by nine basis points over the past four sessions.   Pricing in the swaps market appears to have discounted nearly 100 bp of tightening over the next 12 months.  The two-year Gilt yield has risen by slightly more than 45 bp since the start of last month to 66 bp.  The US two-year yield has increased by nearly 25 bp to almost 45 bp. 

August 30 was the last time the UK 10-year Gilt yield was under 60 bp.  It has more than doubled since then to 1.22% before pulling back before the weekend.   The 10-year breakeven has risen by about 55 bp during the same time.  This suggests a larger rise in real rates than the US may be experiencing.  Despite these interest rate developments, sterling has slipped slightly against the dollar since September 1.  It is the only major country ahead of the US in this monetary cycle whose currency has not risen over this period.  

Encouraged partly by the unexpected surge in Q3 price pressures, the market sees the Reserve Bank of New Zealand as the most aggressive high-income central bank over the next 12 months.  The swaps market is pricing in 150 bp of interest rate hikes.  Indeed, the market is discounting the risk of a move larger than 25 bp at the next RBNZ meeting (concludes first thing in Wellington on November 24).  The implied yield of the December 2021 three-month T-bill futures jumped nearly 20 bp in reaction to the news that CPI accelerated to 4.9% year-over-year from 3.3% in Q2.  The 10-year yield, which rose 25 bp the three weeks before the CPI, surged another 24.5 bp last week.  The New Zealand dollar is leading the other dollar-bloc currencies with a 3.7% gain so far this month.  

Of the three G7 central banks that meet next week, only Canada has experienced a sharp rise in short-term interest rates.  Since the Bank of Canada's meeting last month, the implied yield of the June 2022 Banker Acceptance futures (a three-month interest rate contract) rose more than 40  bp to nearly 1.09% bp by the end of last week. During the same time, the Canadian dollar rallied about 2.6%. 

Strong September jobs data and a robust Bank of Canada business survey (outlook reached a record higher, and 87% of respondents expect inflation over 2%, the highest since 2005) boost confidence that the economy has exited the soft patch.  Monthly GDP had contracted in three of the four months through July. In fact, the market has turned so aggressive that it is pricing in a hike before the central bank anticipated the output gap will close (middle of next year).  The implied yield of the March 2022 BA futures has risen by around 20 bp to 79.5 bp.  In the cash market, the yield of the three-month BA is about 45 bp.  The swaps market is pricing almost 100 bp of tightening over the next 12 months.  

The Bank of Canada will likely confirm its expectation that the output gap will close around the middle of next year.  This assessment is consistent with a rate hike around then. However, the market appears to be leaning toward an earlier move.  Perhaps, it has been encouraged by the subtle shift in Governor Macklem's rhetoric about the transitory nature of the price pressures. He seems to be more cognizant that the elevated price pressures are likely to persist a bit longer than previously anticipated. This may be reflected in the central bank's updated quarterly economic forecasts. Look for the central bank to slow its bond-buying to C$1 bln a week, half the current pace.  

Bank of Japan officials will not dislike last week's September CPI report that showed the headline rate rising above zero for the first time since August 2020.  The core rate, which excludes fresh food and is the BOJ's targeted measure, ticked up to 0.2%, its highest level since March 2020.  Still, it is primarily a function of the surge in energy prices. Excluding both fresh food and energy, deflationary forces are still evident at -0.5%.  Recall that the Q2 GDP price deflator stood at -1.1%, the strongest deflationary thrust in a decade.  

There is little the BOJ apparently thinks it can do at this juncture.  It has slowed its bond and equity purchases but is hesitant to call it tapering as it is not leading to an endpoint.  It will update its forecasts. Previously, it saw inflation rising from 0.6% this year to 0.9% next year and 1.0% in 2023. Its GDP forecast anticipated growth to slow from 3.8% this year to 2.7% in 2022 and 1.3% in 2023. 

The ECB meeting will conclude several hours after the BOJ meeting on October 28.  As far as ECB meetings go, this is not a particularly important one. No new forecasts will be provided.  No new initiatives will be launched. Instead, ECB President Lagarde may explain the different forces impacting prices and why on balance, it still appears that the inflation overshoot will prove transitory.  We note that the annualized pace of CPI in Q3 was about 2.4%, half Q2's annualized rate.  

German and Spanish national October CPI estimates will be available while the ECB meets, and the following data aggregate estimate will be published.  Given the base effect (0.2% increase in October 2020), the rise in energy prices, and the euro's weakness, prudence dictates that the ECB assumes that price pressures have not peaked.  The core rate, which excludes food and energy, stood at 1.9% in September and has not been above 2% since 2002.  

Such data will steel the resolve of the hawks to limit the scope of further accommodation.  It seems almost a given that the Pandemic Emergency Purchase Program will finish at the end of Q1 22.  The big fight now is over QE afterward.  The current Asset Purchase Program is modest (20 bln euros a month) and has various, even if, self-imposed restrictions.  The ECB wants a facility that is more flexible in terms of eligible assets and time of purchases.  The program now seems open-ended:  "The Governing Council expects them to run for as long as necessary to reinforce the accommodative impact of its policy rates, and to end shortly before it starts raising the key ECB interest rates." 

The swaps market is pricing in almost a 10 bps ECB  rate hike in 12 months.  The December 2022 Euribor futures imply a yield of -32 bp compared to the yield of -53 bp of the December 2021 contract. That would seem to indicate that the APP would wind down around the middle of 2022, or maybe a little later. However, some officials seem to favor some kind of standby facility, which can be used as needed, suggesting that the central bank's balance sheet will be a permanent tool in its policy kit.

The day after the ECB meeting, the first estimate of the aggregate Q3 GDP will be released.  Forecasts have been shaved, and the median (Bloomberg survey October 8-14) projection is now for 1.9% vs. 2.2% previously.  Recall that the regional economy surged in Q3 20 before contracting again in Q4 20 and Q1 21.  It rebounded by 2.1% in Q2, which now looks to be the peak.  The median forecast in Bloomberg's survey for Q4 growth is 1% 

As Lagarde's press conference gets underway on October 28, the US will report its preliminary estimate of Q3 GDP.  Disappointing data and a flare-up of covid cases have prodded economists to slash their forecasts.  The Atlanta Fed's GDP tracker is exceptionally pessimistic.  In early August, it was looking at something slightly above 6%, and by the end of the month, it was still at an impressive 5%. By early October, it has fallen to a little more than 1%.  As of October 19, following the disappointing industrial production (1.3% in September and the August series was revised to -0.1% from 0.4%), and housing starts (-1.6% vs. expectations for a flat report, and August's 3.9% increase was cut to 1.2%), the Atlanta Fed's GDPNow shows the US economy practically stagnated (0.5% annualized pace in Q3).  

Economists surveyed by Bloomberg cut their forecasts as well, even if not by as much as the Atlanta Fed's tracker.  The median now sees 2.8% annualized growth in Q3 compared with 5% in the previous survey.  Previously, the median anticipated 5.3% growth in Q4, and that has been revised to 4.9%.  While we suspect there may be downside risk to the median forecast, the Atlanta Fed's tracker seems too dour.  But, even if it is even reasonably accurate, talk of a recession still seems far off the mark.  Growth next year is still expected to be well above trend.  The IMF's latest forecast projects the US economy will expand by 5.2% in 2022, while the World Bank's estimate is 4.2%.  The OECD sees 3.9% growth, while the median Fed official forecast is for 3.8%, the lowest among this selected group.  

The GDP estimate will incorporate September's personal consumption expenditures, released the following day separately, alongside personal income.  Despite more people working, the end of the federal supplemental unemployment compensation likely dragged down income.  The 0.7% increase in retail sales was a pleasant upside surprise, but it also accounts for around 45% of overall consumption.  The median forecast is for PCE to rise by a still-solid 0.6%. However, the market will instead focus on the deflator.   The Fed targets the headline rate at 2% (average over some purposely unspecified period), and the core rate is expected to have ticked up to 4.4% and 3.7%, respectively.  These both would be new cyclical highs.    


Disclaimer

Read More

Continue Reading

Government

CDC Warns Thousands Of Children Sent To ER After Taking Common Sleep Aid

CDC Warns Thousands Of Children Sent To ER After Taking Common Sleep Aid

Authored by Jack Phillips via The Epoch Times (emphasis ours),

A…

Published

on

CDC Warns Thousands Of Children Sent To ER After Taking Common Sleep Aid

Authored by Jack Phillips via The Epoch Times (emphasis ours),

A U.S. Centers for Disease Control (CDC) paper released Thursday found that thousands of young children have been taken to the emergency room over the past several years after taking the very common sleep-aid supplement melatonin.

The Centers for Disease Control and Prevention (CDC) headquarters in Atlanta, Georgia, on April 23, 2020. (Tami Chappell/AFP via Getty Images)

The agency said that melatonin, which can come in gummies that are meant for adults, was implicated in about 7 percent of all emergency room visits for young children and infants “for unsupervised medication ingestions,” adding that many incidents were linked to the ingestion of gummy formulations that were flavored. Those incidents occurred between the years 2019 and 2022.

Melatonin is a hormone produced by the human body to regulate its sleep cycle. Supplements, which are sold in a number of different formulas, are generally taken before falling asleep and are popular among people suffering from insomnia, jet lag, chronic pain, or other problems.

The supplement isn’t regulated by the U.S. Food and Drug Administration and does not require child-resistant packaging. However, a number of supplement companies include caps or lids that are difficult for children to open.

The CDC report said that a significant number of melatonin-ingestion cases among young children were due to the children opening bottles that had not been properly closed or were within their reach. Thursday’s report, the agency said, “highlights the importance of educating parents and other caregivers about keeping all medications and supplements (including gummies) out of children’s reach and sight,” including melatonin.

The approximately 11,000 emergency department visits for unsupervised melatonin ingestions by infants and young children during 2019–2022 highlight the importance of educating parents and other caregivers about keeping all medications and supplements (including gummies) out of children’s reach and sight.

The CDC notes that melatonin use among Americans has increased five-fold over the past 25 years or so. That has coincided with a 530 percent increase in poison center calls for melatonin exposures to children between 2012 and 2021, it said, as well as a 420 percent increase in emergency visits for unsupervised melatonin ingestion by young children or infants between 2009 and 2020.

Some health officials advise that children under the age of 3 should avoid taking melatonin unless a doctor says otherwise. Side effects include drowsiness, headaches, agitation, dizziness, and bed wetting.

Other symptoms of too much melatonin include nausea, diarrhea, joint pain, anxiety, and irritability. The supplement can also impact blood pressure.

However, there is no established threshold for a melatonin overdose, officials have said. Most adult melatonin supplements contain a maximum of 10 milligrams of melatonin per serving, and some contain less.

Many people can tolerate even relatively large doses of melatonin without significant harm, officials say. But there is no antidote for an overdose. In cases of a child accidentally ingesting melatonin, doctors often ask a reliable adult to monitor them at home.

Dr. Cora Collette Breuner, with the Seattle Children’s Hospital at the University of Washington, told CNN that parents should speak with a doctor before giving their children the supplement.

“I also tell families, this is not something your child should take forever. Nobody knows what the long-term effects of taking this is on your child’s growth and development,” she told the outlet. “Taking away blue-light-emitting smartphones, tablets, laptops, and television at least two hours before bed will keep melatonin production humming along, as will reading or listening to bedtime stories in a softly lit room, taking a warm bath, or doing light stretches.”

In 2022, researchers found that in 2021, U.S. poison control centers received more than 52,000 calls about children consuming worrisome amounts of the dietary supplement. That’s a six-fold increase from about a decade earlier. Most such calls are about young children who accidentally got into bottles of melatonin, some of which come in the form of gummies for kids, the report said.

Dr. Karima Lelak, an emergency physician at Children’s Hospital of Michigan and the lead author of the study published in 2022 by the CDC, found that in about 83 percent of those calls, the children did not show any symptoms.

However, other children had vomiting, altered breathing, or other symptoms. Over the 10 years studied, more than 4,000 children were hospitalized, five were put on machines to help them breathe, and two children under the age of two died. Most of the hospitalized children were teenagers, and many of those ingestions were thought to be suicide attempts.

Those researchers also suggested that COVID-19 lockdowns and virtual learning forced more children to be at home all day, meaning there were more opportunities for kids to access melatonin. Also, those restrictions may have caused sleep-disrupting stress and anxiety, leading more families to consider melatonin, they suggested.

The Associated Press contributed to this report.

Tyler Durden Mon, 03/11/2024 - 21:40

Read More

Continue Reading

International

Red Candle In The Wind

Red Candle In The Wind

By Benjamin PIcton of Rabobank

February non-farm payrolls superficially exceeded market expectations on Friday by…

Published

on

Red Candle In The Wind

By Benjamin PIcton of Rabobank

February non-farm payrolls superficially exceeded market expectations on Friday by printing at 275,000 against a consensus call of 200,000. We say superficially, because the downward revisions to prior months totalled 167,000 for December and January, taking the total change in employed persons well below the implied forecast, and helping the unemployment rate to pop two-ticks to 3.9%. The U6 underemployment rate also rose from 7.2% to 7.3%, while average hourly earnings growth fell to 0.2% m-o-m and average weekly hours worked languished at 34.3, equalling pre-pandemic lows.

Undeterred by the devil in the detail, the algos sprang into action once exchanges opened. Market darling NVIDIA hit a new intraday high of $974 before (presumably) the humans took over and sold the stock down more than 10% to close at $875.28. If our suspicions are correct that it was the AIs buying before the humans started selling (no doubt triggering trailing stops on the way down), the irony is not lost on us.

The 1-day chart for NVIDIA now makes for interesting viewing, because the red candle posted on Friday presents quite a strong bearish engulfing signal. Volume traded on the day was almost double the 15-day simple moving average, and similar price action is observable on the 1-day charts for both Intel and AMD. Regular readers will be aware that we have expressed incredulity in the past about the durability the AI thematic melt-up, so it will be interesting to see whether Friday’s sell off is just a profit-taking blip, or a genuine trend reversal.

AI equities aside, this week ought to be important for markets because the BTFP program expires today. That means that the Fed will no longer be loaning cash to the banking system in exchange for collateral pledged at-par. The KBW Regional Banking index has so far taken this in its stride and is trading 30% above the lows established during the mini banking crisis of this time last year, but the Fed’s liquidity facility was effectively an exercise in can-kicking that makes regional banks a sector of the market worth paying attention to in the weeks ahead. Even here in Sydney, regulators are warning of external risks posed to the banking sector from scheduled refinancing of commercial real estate loans following sharp falls in valuations.

Markets are sending signals in other sectors, too. Gold closed at a new record-high of $2178/oz on Friday after trading above $2200/oz briefly. Gold has been going ballistic since the Friday before last, posting gains even on days where 2-year Treasury yields have risen. Gold bugs are buying as real yields fall from the October highs and inflation breakevens creep higher. This is particularly interesting as gold ETFs have been recording net outflows; suggesting that price gains aren’t being driven by a retail pile-in. Are gold buyers now betting on a stagflationary outcome where the Fed cuts without inflation being anchored at the 2% target? The price action around the US CPI release tomorrow ought to be illuminating.

Leaving the day-to-day movements to one side, we are also seeing further signs of structural change at the macro level. The UK budget last week included a provision for the creation of a British ISA. That is, an Individual Savings Account that provides tax breaks to savers who invest their money in the stock of British companies. This follows moves last year to encourage pension funds to head up the risk curve by allocating 5% of their capital to unlisted investments.

As a Hail Mary option for a government cruising toward an electoral drubbing it’s a curious choice, but it’s worth highlighting as cash-strapped governments increasingly see private savings pools as a funding solution for their spending priorities.

Of course, the UK is not alone in making creeping moves towards financial repression. In contrast to announcements today of increased trade liberalisation, Australian Treasurer Jim Chalmers has in the recent past flagged his interest in tapping private pension savings to fund state spending priorities, including defence, public housing and renewable energy projects. Both the UK and Australia appear intent on finding ways to open up the lungs of their economies, but government wants more say in directing private capital flows for state goals.

So, how far is the blurring of the lines between free markets and state planning likely to go? Given the immense and varied budgetary (and security) pressures that governments are facing, could we see a re-up of WWII-era Victory bonds, where private investors are encouraged to do their patriotic duty by directly financing government at negative real rates?

That would really light a fire under the gold market.

Tyler Durden Mon, 03/11/2024 - 19:00

Read More

Continue Reading

Spread & Containment

Fauci Deputy Warned Him Against Vaccine Mandates: Email

Fauci Deputy Warned Him Against Vaccine Mandates: Email

Authored by Zachary Stieber via The Epoch Times (emphasis ours),

Mandating COVID-19…

Published

on

Fauci Deputy Warned Him Against Vaccine Mandates: Email

Authored by Zachary Stieber via The Epoch Times (emphasis ours),

Mandating COVID-19 vaccination was a mistake due to ethical and other concerns, a top government doctor warned Dr. Anthony Fauci after Dr. Fauci promoted mass vaccination.

Coercing or forcing people to take a vaccine can have negative consequences from a biological, sociological, psychological, economical, and ethical standpoint and is not worth the cost even if the vaccine is 100% safe,” Dr. Matthew Memoli, director of the Laboratory of Infectious Diseases clinical studies unit at the U.S. National Institute of Allergy and Infectious Diseases (NIAID), told Dr. Fauci in an email.

“A more prudent approach that considers these issues would be to focus our efforts on those at high risk of severe disease and death, such as the elderly and obese, and do not push vaccination on the young and healthy any further.”

Dr. Anthony Fauci, ex-director of the National Institute of Allergy and Infectious Diseases (NIAID. in Washington on Jan. 8, 2024. (Madalina Vasiliu/The Epoch Times)

Employing that strategy would help prevent loss of public trust and political capital, Dr. Memoli said.

The email was sent on July 30, 2021, after Dr. Fauci, director of the NIAID, claimed that communities would be safer if more people received one of the COVID-19 vaccines and that mass vaccination would lead to the end of the COVID-19 pandemic.

“We’re on a really good track now to really crush this outbreak, and the more people we get vaccinated, the more assuredness that we’re going to have that we’re going to be able to do that,” Dr. Fauci said on CNN the month prior.

Dr. Memoli, who has studied influenza vaccination for years, disagreed, telling Dr. Fauci that research in the field has indicated yearly shots sometimes drive the evolution of influenza.

Vaccinating people who have not been infected with COVID-19, he said, could potentially impact the evolution of the virus that causes COVID-19 in unexpected ways.

“At best what we are doing with mandated mass vaccination does nothing and the variants emerge evading immunity anyway as they would have without the vaccine,” Dr. Memoli wrote. “At worst it drives evolution of the virus in a way that is different from nature and possibly detrimental, prolonging the pandemic or causing more morbidity and mortality than it should.”

The vaccination strategy was flawed because it relied on a single antigen, introducing immunity that only lasted for a certain period of time, Dr. Memoli said. When the immunity weakened, the virus was given an opportunity to evolve.

Some other experts, including virologist Geert Vanden Bossche, have offered similar views. Others in the scientific community, such as U.S. Centers for Disease Control and Prevention scientists, say vaccination prevents virus evolution, though the agency has acknowledged it doesn’t have records supporting its position.

Other Messages

Dr. Memoli sent the email to Dr. Fauci and two other top NIAID officials, Drs. Hugh Auchincloss and Clifford Lane. The message was first reported by the Wall Street Journal, though the publication did not publish the message. The Epoch Times obtained the email and 199 other pages of Dr. Memoli’s emails through a Freedom of Information Act request. There were no indications that Dr. Fauci ever responded to Dr. Memoli.

Later in 2021, the NIAID’s parent agency, the U.S. National Institutes of Health (NIH), and all other federal government agencies began requiring COVID-19 vaccination, under direction from President Joe Biden.

In other messages, Dr. Memoli said the mandates were unethical and that he was hopeful legal cases brought against the mandates would ultimately let people “make their own healthcare decisions.”

“I am certainly doing everything in my power to influence that,” he wrote on Nov. 2, 2021, to an unknown recipient. Dr. Memoli also disclosed that both he and his wife had applied for exemptions from the mandates imposed by the NIH and his wife’s employer. While her request had been granted, his had not as of yet, Dr. Memoli said. It’s not clear if it ever was.

According to Dr. Memoli, officials had not gone over the bioethics of the mandates. He wrote to the NIH’s Department of Bioethics, pointing out that the protection from the vaccines waned over time, that the shots can cause serious health issues such as myocarditis, or heart inflammation, and that vaccinated people were just as likely to spread COVID-19 as unvaccinated people.

He cited multiple studies in his emails, including one that found a resurgence of COVID-19 cases in a California health care system despite a high rate of vaccination and another that showed transmission rates were similar among the vaccinated and unvaccinated.

Dr. Memoli said he was “particularly interested in the bioethics of a mandate when the vaccine doesn’t have the ability to stop spread of the disease, which is the purpose of the mandate.”

The message led to Dr. Memoli speaking during an NIH event in December 2021, several weeks after he went public with his concerns about mandating vaccines.

“Vaccine mandates should be rare and considered only with a strong justification,” Dr. Memoli said in the debate. He suggested that the justification was not there for COVID-19 vaccines, given their fleeting effectiveness.

Julie Ledgerwood, another NIAID official who also spoke at the event, said that the vaccines were highly effective and that the side effects that had been detected were not significant. She did acknowledge that vaccinated people needed boosters after a period of time.

The NIH, and many other government agencies, removed their mandates in 2023 with the end of the COVID-19 public health emergency.

A request for comment from Dr. Fauci was not returned. Dr. Memoli told The Epoch Times in an email he was “happy to answer any questions you have” but that he needed clearance from the NIAID’s media office. That office then refused to give clearance.

Dr. Jay Bhattacharya, a professor of health policy at Stanford University, said that Dr. Memoli showed bravery when he warned Dr. Fauci against mandates.

“Those mandates have done more to demolish public trust in public health than any single action by public health officials in my professional career, including diminishing public trust in all vaccines.” Dr. Bhattacharya, a frequent critic of the U.S. response to COVID-19, told The Epoch Times via email. “It was risky for Dr. Memoli to speak publicly since he works at the NIH, and the culture of the NIH punishes those who cross powerful scientific bureaucrats like Dr. Fauci or his former boss, Dr. Francis Collins.”

Tyler Durden Mon, 03/11/2024 - 17:40

Read More

Continue Reading

Trending